The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
The Visian ICL (Implantable Collamer Lens) is an exquisitely precise technology for the correction of high degrees of nearsightedness -- much higher than the reach of laser refractive surgery such as LASIK and PRK. Given the price of the ICL and the intraocular surgey required for its...
"He who pays the fiddler calls the tune." Here's an example of the fiddler pro-actively asking the guy in the room with the deepest pocket what he'd like to hear. If it's not something in the current repertoire, the fiddler seems willing to learn. However, by the time he's got...
The media reporting on the FDA hearings on LASIK has generally highlighted unhappy patients' stories and the comments of FDA officials and panel members. However, The Washington Post's Lauran Neergard has written an insightful article that foresees an important future trend in refractive surgery....
Presbyopia correcting IOLs currently represent 5% of all IOLs implanted in the United States (about 3.5 million per year). The products available in this category include the ReSTOR multifocal IOL (Alcon), the ReZoom multifocal IOL (AMO) and the cyrstalens accommodative IOL (eyeonics). Although...
Rather than getting gobbled up by one of the big three players in Ophthalmology (B & L, Alcon and AMO), eyeonics is looking to go it alone into the public arena. The crystalens remains the only approved accommodative intraocular lens, but faces strong competition from the multifocals. ...
Alcon has suffered with its LADARVision system recalls and lawsuits, and has looked particularly troubled following AMO's acquisition of VISX. Although AMO/VISX remains the market leader for refractive correction, the Allegretto represents new technology with potential advantages in terms of accuracy...
Currently the ophthalmic device market is organized into an oligopoly including Alcon, AMO and Bausch. AMO has shown fairly dramatic growth with its acquisition of VISX, Intralase and Wavefront Sciences. However, AMO's potential acquisition of Bausch is on a grander scale. There are...
Refractive surgery is taken for granted by patients to "get rid of their glasses and contact lenses". They rarely consider the possibility of loss of vision.
This article describes the perspective of a retinal specialist on the Avastin/Lucentis controversy. In mid-February the National Institutes of Health announced that it would conduct a head to head trial comparing the effectiveness of Lucentis and Avastin for the treatment of wet age...